SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+metastatic breast cancer (MBC)

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorCiruelos, E. M.
dc.contributor.authorPernas, S.
dc.contributor.authorPerello, A.
dc.contributor.authorLopez, A.
dc.contributor.authorSalvador Bofill, F. J.
dc.contributor.authorCejalvo, J. M.
dc.contributor.authorBlancas, I.
dc.contributor.authorPonce Lorenzo, J.
dc.contributor.authorServitja, S.
dc.contributor.authorPerez, M.
dc.contributor.authorCruz, J.
dc.contributor.authorAlbacar, C.
dc.contributor.authorEscriva-de-Romani, S. I.
dc.contributor.authorGuerra, J. A.
dc.contributor.authorGonzalez-Santiago, S.
dc.contributor.authorSanfeliu, E.
dc.contributor.authorRodriguez, C.
dc.contributor.authorTolosa, P.
dc.contributor.authorFerrero-Cafiero, J. M.
dc.contributor.authorPrat, A.
dc.contributor.authoraffiliation[Ciruelos, E. M.] Hosp Univ 12 Octubre, SOLTI Breast Canc Res Grp, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Tolosa, P.] Hosp Univ 12 Octubre, SOLTI Breast Canc Res Grp, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Pernas, S.] Inst Catala dOncol, SOLTI Breast Canc Res Grp, Med Oncol Dept, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Perello, A.] Hosp Son Espases, Med Oncol Dept, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Lopez, A.] Complejo Asistencia Univ Leon, Med Oncol Dept, Leon, Spain
dc.contributor.authoraffiliation[Salvador Bofill, F. J.] Complejo Asistencia Univ Leon, Med Oncol Dept, Leon, Spain
dc.contributor.authoraffiliation[Cejalvo, J. M.] Hosp Univ Virgen Rocio, Med Oncol Dept, Seville, Spain
dc.contributor.authoraffiliation[Blancas, I.] Univ Valencia, Hosp Clin, INCLIVA Inst Invest Sanitaria, Med Oncol Dept, Valencia, Spain
dc.contributor.authoraffiliation[Ponce Lorenzo, J.] Univ Granada, Hosp Univ Clin San Cecilio Granada, Oncol Unit, Med Dept, Granada, Spain
dc.contributor.authoraffiliation[Servitja, S.] Univ Gen Hosp Alicante, Oncol Unit, Alicante, Spain
dc.contributor.authoraffiliation[Perez, M.] Hosp Mar, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Cruz, J.] CHUA CORUNA, Med Oncol Dept, La Coruna, Spain
dc.contributor.authoraffiliation[Albacar, C.] Hosp Univ Canarias, Med Oncol Dept, Santa Cruz De Tenerife, Spain
dc.contributor.authoraffiliation[Escriva-de-Romani, S. I.] Hosp Univ Sant Joan Reus, Oncol, Reus, Spain
dc.contributor.authoraffiliation[Guerra, J. A.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
dc.contributor.authoraffiliation[Gonzalez-Santiago, S.] Hosp Univ Fuenlabrada, Med Oncol Dept, Madrid, Spain
dc.contributor.authoraffiliation[Sanfeliu, E.] August Pi i Sunyer Biomed Res Inst IDIBAPS, Pathol Lab, Barcelona, Spain
dc.contributor.authoraffiliation[Rodriguez, C.] Hosp Univ Salamanca, Med Oncol Dept, Salamanca, Spain
dc.contributor.authoraffiliation[Ferrero-Cafiero, J. M.] SOLTI HQ, Clin Res Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Prat, A.] Hosp Clin Barcelona, SOLTI Breast Canc Res Grp, Med Oncol Dept, Barcelona, Spain
dc.contributor.funderRoche
dc.date.accessioned2025-01-07T14:07:17Z
dc.date.available2025-01-07T14:07:17Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.615
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.615
dc.identifier.urihttps://hdl.handle.net/10668/26153
dc.identifier.wosID700527700311
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS511-S511
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleSOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+metastatic breast cancer (MBC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario San Cecilio
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía